IP Library Granted Patent US 7,235,675
Granted Patent B2
US 7,235,675 · App. 10/900,447 · Granted Jun 26, 2007

Conjugates of mycophenolic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,235,675
App. No.
10/900,447
Granted
Jun 26, 2007
Kind
B2
Abstract

The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.

Claims (11)

1. A ligand-inhibitor conjugate with the structure

wherein n=1 and X is selected from the group consisting of —O—CONH—(CH 2 ) 2 -NH-thyroxine, —O—CONH—(CH 2 ) 2 —NHC(═C)—(CH 2 ) 4 -theophylline, —NH—CO—(CH 2 ) 3 -phenytoin, —O—CO[NH-gentamicin], —NH—CO-Ph-CO[NH-gentamicin] wherein Ph is phenyl, 5′-[[[(digoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-, 5′-[[[(digitoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-, and

2. The conjugate of claim 1 wherein X is —O—CONH—(CH 2 ) 2 —NH-thyroxine.

3. The conjugate of claim 1 wherein X is —O—CONH—(CH 2 ) 2 —NHC(═C)—(CH 2 ) 4 -theophylline.

4. The conjugate of claim 1 wherein X is

5. The conjugate of claim 1 wherein X is —NH—CO—(CH 2 ) 3 -phenytoin.

6. The conjugate of claim 1 wherein X is —O—CO[NH-gentamicin].

7. The conjugate of claim 1 wherein X is —NH—CO-Ph-CO[NH-gentamicin] and Ph is phenyl.

8. The conjugate of claim 1 wherein X is 5′-[[[(digoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-.

9. The conjugate of claim 1 wherein X is 5′-[[[(digitoxin(1,4-oxazepin))-4-yl]-phenyl-4-carbonyl]amino]-.

10. The compound of claim 1 that is 5′-[(theophylline-8-butyramidoethylaminocarbonyloxy)isoprenyl]-MPA.